CN113336801A - Tetravalent platinum complex containing BET inhibitor and application - Google Patents
Tetravalent platinum complex containing BET inhibitor and application Download PDFInfo
- Publication number
- CN113336801A CN113336801A CN202110637310.4A CN202110637310A CN113336801A CN 113336801 A CN113336801 A CN 113336801A CN 202110637310 A CN202110637310 A CN 202110637310A CN 113336801 A CN113336801 A CN 113336801A
- Authority
- CN
- China
- Prior art keywords
- platinum complex
- bet inhibitor
- tetravalent platinum
- compound
- cisplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 229910052697 platinum Inorganic materials 0.000 title claims abstract description 49
- 229940125763 bromodomain inhibitor Drugs 0.000 title claims abstract description 38
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 28
- 229960004316 cisplatin Drugs 0.000 claims abstract description 27
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 15
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 15
- 229940041181 antineoplastic drug Drugs 0.000 claims description 15
- 201000005202 lung cancer Diseases 0.000 claims description 15
- 208000020816 lung neoplasm Diseases 0.000 claims description 15
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 15
- 201000002528 pancreatic cancer Diseases 0.000 claims description 15
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 31
- 229940125904 compound 1 Drugs 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091005625 BRD4 Proteins 0.000 description 2
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 2
- 102000001805 Bromodomains Human genes 0.000 description 2
- 108050009021 Bromodomains Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- YIDSTEJLDQMWBR-UHFFFAOYSA-N 1-isocyanatododecane Chemical compound CCCCCCCCCCCCN=C=O YIDSTEJLDQMWBR-UHFFFAOYSA-N 0.000 description 1
- DYQFCTCUULUMTQ-UHFFFAOYSA-N 1-isocyanatooctane Chemical compound CCCCCCCCN=C=O DYQFCTCUULUMTQ-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 description 1
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 1
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 description 1
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 1
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091057508 Myc family Proteins 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- OCNZHGHKKQOQCZ-CLFAGFIQSA-N [(z)-octadec-9-enoyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(=O)CCCCCCC\C=C/CCCCCCCC OCNZHGHKKQOQCZ-CLFAGFIQSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NWADXBLMWHFGGU-UHFFFAOYSA-N dodecanoic anhydride Chemical compound CCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCC NWADXBLMWHFGGU-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- -1 ethylene, propylene Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- PKHMTIRCAFTBDS-UHFFFAOYSA-N hexanoyl hexanoate Chemical compound CCCCCC(=O)OC(=O)CCCCC PKHMTIRCAFTBDS-UHFFFAOYSA-N 0.000 description 1
- ANJPRQPHZGHVQB-UHFFFAOYSA-N hexyl isocyanate Chemical compound CCCCCCN=C=O ANJPRQPHZGHVQB-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a tetravalent platinum complex containing a BET inhibitor, which has a structure shown as a general formula I:
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a tetravalent platinum complex containing a BET inhibitor and application thereof in preparation of antitumor drugs.
Background
The platinum antineoplastic drugs are widely used for treating malignant tumors clinically. Currently, the FDA in the united states has approved three platinum drugs on the market, including cisplatin, carboplatin, and oxaliplatin. Cisplatin can be used for treating ovarian cancer, prostatic cancer, testis cancer, lung cancer, nasopharyngeal carcinoma, esophageal carcinoma, malignant lymphoma, head and neck squamous cell carcinoma, thyroid carcinoma, and osteogenic sarcoma. Carboplatin is a second-generation platinum drug, is a broad-spectrum antitumor drug, has no cross drug resistance with other antitumor drugs, has cross drug resistance with cisplatin, and is mainly used for small cell lung cancer, ovarian cancer, testicular tumor, head and neck squamous cell carcinoma and the like. Oxaliplatin is a third-generation platinum drug, has good curative effect on colorectal cancer and ovarian cancer, and has certain curative effect on gastric cancer, non-Hodgkin lymphoma, non-small cell lung cancer and head and neck tumors. The platinum antineoplastic drugs are the most widely used chemotherapeutic drugs for tumor patients in China, but the platinum antineoplastic drugs are easy to generate drug resistance after long-term use and have side effects of renal toxicity, gastrointestinal adverse reactions, blood toxicity and the like. The method for oxidizing bivalent platinum drugs into tetravalent platinum and further structurally introducing other antitumor effect groups is a hot research and development field of platinum antitumor drugs in recent years. The literature reports that anti-inflammatory drugs such as aspirin, naproxen and the like can exert good synergistic anti-tumor effect when introduced into tetravalent platinum, and have the advantages of low toxic and side effects, better anti-tumor effect in nude mice and the like.
The bromodomain and the super-terminal domain (BET) family belong to the bromodomain protein family, are important epigenetic regulatory proteins and transcriptional regulatory proteins, and are involved in regulating various biological processes such as cell growth, cell cycle progression, proliferation differentiation, apoptosis necrosis, and the like. The research finds that the BET family is up-regulated in various tumors and is closely related to the occurrence and development of various malignant tumors. The BET family of proteins shares 4 members, namely BRD2, BRD3, BRD4, which are widely expressed, and BRDT, which is normally expressed only in testicular tissue. The family directly regulates MYC family gene expression, and MYC amplification or overexpression is common mutation in various blood tumors and solid tumors such as lung cancer, gastric cancer, breast cancer and the like. At present, clinical antitumor test researches are widely carried out on BET-targeted small-molecule inhibitors (particularly BRD4 inhibitors), a plurality of hematological tumor researches have positive results, and preclinical researches on solid tumors such as prostate cancer, breast cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer and the like also show that the BET inhibitor can effectively inhibit tumor growth, so that the BET inhibitor is hopeful to become a broad-spectrum antitumor targeted drug. However, the present research results show that BET inhibitors are effective only on a part of cell lines in various tumors, and the mechanism thereof is not clear.
Disclosure of Invention
The invention aims to provide a tetravalent platinum complex containing a BET inhibitor, which has a brand-new framework structure and excellent antitumor activity and can be used for preparing antitumor drugs.
The second purpose of the invention is to provide the application of the tetravalent platinum complex containing the BET inhibitor in preparing the antitumor drugs.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
the first aspect of the invention provides a tetravalent platinum complex containing a BET inhibitor, and the structure of the tetravalent platinum complex is shown as the general formula I:
r is selected from H,
R1Selected from the group consisting of branched or straight chain saturated C1-C20 alkyl, branched or straight chain unsaturated C1-C20 alkyl,
The term alkyl refers to a straight or branched chain saturated or unsaturated aliphatic hydrocarbon group containing from 1 to 20 carbon atoms, for example: methyl, ethyl, propyl, isopropyl, butyl, t-butyl, ethylene, propylene, and the like.
More preferably, in the general formula I, R1Is selected from-CF3、-CH3、-CH2CH3、-CH(CH3)2、-(CH2)2CH3、-(CH2)4CH3、-(CH2)5CH3、-(CH2)6CH3、-(CH2)7CH3、-(CH2)10CH3、-(CH2)11CH3、-(CH2)12CH3、-(CH2)13CH3、-CH＝CHCH3、-(CH2)7CH＝CH(CH2)6CH3、-(CH2)7CH＝CH(CH2)7CH3、
Most preferably, the tetravalent platinum complex containing a BET inhibitor is one of the following structures:
the invention also provides an application of the tetravalent platinum complex containing the BET inhibitor in preparation of an anti-tumor drug.
The tetravalent platinum complex containing a BET inhibitor is preferably:
the tumor is selected from lung cancer, pancreatic cancer, hepatocarcinoma, and cisplatin-resistant lung cancer.
Due to the adoption of the technical scheme, the invention has the following advantages and beneficial effects:
aiming at the defects that the BET inhibitor is only effective on partial tumor cell lines and bivalent platinum drugs are used, the invention connects the BET inhibitor and cisplatin to construct a tetravalent platinum complex containing the BET inhibitor. The invention utilizes the advantages of the tetravalent platinum complex to exert the synergistic antitumor effect of the BET inhibitor and the cisplatin. The tetravalent platinum complex containing the BET inhibitor shows broad-spectrum and excellent in-vitro anti-tumor activity, the activity of the tetravalent platinum complex is obviously superior to that of cisplatin, the BET inhibitor and the combined use of the cisplatin and the BET inhibitor in a ratio of 1:1, and the tetravalent platinum complex has great potential for developing a novel broad-spectrum anti-tumor medicament.
The tetravalent platinum complex containing the BET inhibitor provided by the invention has a relatively obvious proliferation inhibition effect on lung cancer A549, pancreatic cancer Panc-1, pancreatic cancer CFPAC-1, breast cancer MDA-MB-231, cisplatin-resistant lung adenocarcinoma A549/CDDP and liver cancer HepG2, and the antitumor activity of part of compounds is obviously superior to that of cisplatin, so that the tetravalent platinum complex can be used as an antitumor candidate drug for more intensive research. For example, the compound 9 shows the optimal antitumor activity on the whole, and has half inhibition concentration IC (integrated circuit) of lung cancer A549, pancreatic cancer Panc-1, pancreatic cancer CFPAC-1, liver cancer HepG2, breast cancer MDA-MB-231 and cis-platinum-resistant lung cancer A54950Are all lower than 4 mu M and are obviously better than the combination of cisplatin, BET inhibitor and cisplatin. In addition, a plurality of compounds have extremely strong inhibitory activity on pancreatic cancer CFPAC-1, such as IC of compounds 7-10 on CFPAC-150Respectively 0.56 mu M, 0.80 mu M, 0.20 mu M and 0.68 mu M, which is obviously superior to the combination of cisplatin, BET inhibitor and cisplatin. The compound provided by the invention has a brand-new framework structure and excellent anti-tumor activity, and can be used for developing anti-tumor drugs.
Aiming at the technical problems of large side effect, low activity and the like of the existing divalent platinum antitumor drugs and BET inhibitors in antitumor treatment, the invention provides a tetravalent platinum complex containing the BET inhibitors, which can fully utilize the advantages of the divalent platinum antitumor drugs and the BET inhibitors, utilize the unique antitumor mechanism of the BET inhibitors, solve the drug resistance of the platinum drugs and play an excellent synergistic antitumor effect.
The tetravalent platinum complex containing the BET inhibitor has the advantages of simple synthetic route, easily obtained synthetic raw materials and easily realized synthetic method.
Detailed Description
In order to more clearly illustrate the invention, the invention is further described below in connection with preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.
The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers.
The chemical structural formula of the compound prepared in the following example,1H-NMR、13The C-NMR and HRMS data are shown in Table 1, wherein the numbers 1 to 11 correspond to the compounds 1 to 11 prepared in examples 1 to 11, respectively.
TABLE 1 chemical structural formulas of target compounds 1 to 11,1H-NMR、13C-NMR and HRMS data
Example 1
Synthesis of Compound 1:
and adding 1.0g of cisplatin, namely the compound II, into 25mL of 30% hydrogen peroxide, reacting for 2 hours at 60 ℃, filtering, and standing the filtrate to obtain yellow needle-shaped solid 0.95g of oxoplatin, namely the compound III, wherein the yield is 85%.
Compound IV (purchased from scientific and scientific technologies, Inc. in Jilin, 30mg, 0.075mmol), TBTU (31mg, 0.095mmol) and triethylamine (9.5mg, 0.095mmol) were added sequentially to 2mL of dry DMF and stirred at room temperature for 10min, followed by compound III (25mg, 0.075mmol) and stirring under nitrogen at room temperature for 12 h. After the reaction was completed, the solvent was evaporated to dryness, and the residue was purified by silica gel column chromatography (DCM: MeOH ═ 20: 1) to give compound 1 as a white solid (38mg, yield 70%).
Example 2
Synthesis of Compound 2
Compound 1(30mg, 0.042mmol) and Compound IV (17mg, 0.043mmol) were added to DMF (2mL), HBTU (19mg, 0.05mmol) and DIPEA (6.5mg, 0.05mmol) were added and the reaction stirred at room temperature for 12 h; after completion of the reaction, the solvent was evaporated to dryness, and the residue was purified by silica gel column chromatography to give compound 2(22mg, yield 48%) as a pale yellow solid.
Example 3
Synthesis of Compound 3
Compound 1(30mg, 0.042mmol) and acetic anhydride (5.1mg, 0.050mmol) were dissolved in DMF (2mL) and reacted for 12h, after which the solvent was evaporated to dryness and the residue was purified by silica gel column chromatography to give compound 3(22mg, yield 69%) as a white solid.
Example 4
Synthesis of Compound 4
Referring to example 3, compound 1(30mg, 0.042mmol) and trifluoroacetic anhydride (10.5mg, 0.050mmol) were reacted in DMF (2mL) to give compound 4(23mg, yield 67%) as a white solid.
Example 5
Synthesis of Compound 5
Referring to example 3, compound 1(30mg, 0.042mmol) was reacted with n-hexanoic anhydride (11mg, 0.05mmol) in DMF (2mL) to give compound 5 as a white solid (25mg, yield 73%).
Example 6
Synthesis of Compound 6
Referring to example 3, compound 1(30mg, 0.042mmol) and lauric anhydride (19mg, 0.05mmol) were dissolved in DMF (2mL), stirred at 60 ℃ for 12h, after the reaction was completed, the solvent was evaporated to dryness, and the residue was purified by silica gel column chromatography (DCM/MeOH ═ 20: 1) to give compound 6(26mg, yield 69%) as a white solid.
Example 7
Synthesis of Compound 7
Referring to example 3, compound 1(30mg, 0.042mmol) and hexyl isocyanate (6.4mg, 0.05mmol) were dissolved in DMF (2mL) and reacted to give compound 7(28mg, yield 79%) as a white solid.
Example 8
Synthesis of Compound 8
Referring to example 3, compound 1(30mg, 0.042mmol) and octyl isocyanate (7.7mg, 0.05mmol) were reacted in DMF (2mL) to give compound 8(25mg, yield 68%) as a white solid.
Example 9
Synthesis of Compound 9
Referring to example 3, compound 1(30mg, 0.042mmol) and dodecyl isocyanate (10.6mg, 0.05mmol) were reacted in DMF (2mL) to give compound 9(30mg, yield 77%) as a white solid.
Example 10
Synthesis of Compound 10
Referring to example 3, compound 1(30mg, 0.042mmol) and oleic anhydride (27mg, 0.05mmol) were reacted in DMF (2mL) to give compound 10 as a pale yellow solid (32mg, yield 78%).
Example 11
Synthesis of Compound 11
Referring to the procedure of example 2, compound 1(30mg, 0.042mmol) and naproxen (9.6mg, 0.042mmol) were dissolved in DMF (2mL), HBTU (19mg, 0.05mmol) and DIPEA (6.5mg, 0.05mmol) were added, the reaction was stirred at room temperature for 12h, and compound 11 was purified by column chromatography as a white solid (21mg, yield 54%).
Example 12
The compound prepared in the embodiment 1-11 of the invention is used as a test compound for the antitumor activity test: the compound of the present invention is tested for inhibition of tumor cell proliferation by the conventional CKK-8 method.
The cell lines are selected from lung cancer A549, pancreatic cancer Panc-1, pancreatic cancer CFPAC-1, liver cancer HepG2, breast cancer MDA-MB-231 and cisplatin-resistant lung cancer A549 which are purchased from Shanghai Living sciences research institute cell banks. The culture solution is DMEM + 10% NBS + double antibody.
Preparing a sample solution: test compounds were dissolved in DMSO (Merck) to prepare a 10mM stock solution. The mother liquor was diluted with the medium to give drugs at final concentrations of 50. mu.M, 25. mu.M, 10. mu.M, 5. mu.M, 1. mu.M, 0.5. mu.M, 0.25. mu.M and 0.125. mu.M, respectively.
The concentration of each hole of a 96-hole plate is 8 multiplied by 104100 μ L of cell suspension per mL, 8000 cells/well, at 37 deg.C with 5% CO2In the incubator. After 24 hours, the supernatant was aspirated, and the sample solution containing the test compound and the control solution were added thereto at 100. mu.L/well and allowed to act at 37 ℃ for 72 hours. Adding CKK-810 mu L into each well, placing in an incubator, measuring 570nm OD value with MK-2 full-automatic enzyme standard instrument after 1 hour of action, and calculating half inhibitory concentration IC50。
The antitumor activity of the compounds to be tested is detailed in table 2, wherein samples 1 to 11 refer to tetravalent platinum complexes containing BET inhibitors prepared in the corresponding examples, for example, compound 1 refers to the compound obtained in example 1, and the same is true. The positive drugs were BET inhibitors (compound IV in example 1), Cisplatin (CDDP) and cisplatin mixed with BET inhibitor 1:1 (CDDP + IV).
TABLE 2 half inhibitory concentration IC of partial compounds of the invention on tumor cells50(Unit: μ M)
The results in Table 2 show that the compounds prepared in examples 1-11 of the invention have broad-spectrum and excellent antitumor activity, and have excellent proliferation inhibition effects on lung cancer A549, pancreatic cancer Panc-1, pancreatic cancer CFPAC-1, liver cancer HepG2, breast cancer MDA-MB-231 and cis-platinum-resistant lung cancer A549. The antitumor activity of part of compounds is stronger than that of cisplatin, if the compound 9 totally shows the optimal antitumor activity, the half inhibition concentration IC of the compound on lung cancer A549, pancreatic cancer Panc-1, pancreatic cancer CFPAC-1, liver cancer HepG2, breast cancer MDA-MB-231 and cis-platinum-resistant lung cancer A54950Are all lower than 4 mu M and are obviously better than the combination of cisplatin, BET inhibitor and cisplatin. In addition, a plurality of compounds have extremely strong inhibitory activity on pancreatic cancer CFPAC-1, such as IC of compounds 7-10 on CFPAC-150Respectively 0.56 mu M, 0.80 mu M, 0.20 mu M and 0.68 mu M, which is obviously superior to the combination of cisplatin, BET inhibitor and cisplatin.
Although the present invention has been described with reference to a preferred embodiment, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (6)
1. A tetravalent platinum complex containing a BET inhibitor is characterized in that the structure is shown as a general formula I:
r is selected from H,
R1Selected from the group consisting of branched or straight chain saturated C1-C20 alkyl, branched or straight chain unsaturated C1-C20 alkyl,
2. The tetravalent platinum complex with BET inhibitor according to claim 1, wherein in the formula I, R1Is selected from-CF3、-CH3、-CH2CH3、-CH(CH3)2、-(CH2)2CH3、-(CH2)4CH3、-(CH2)5CH3、-(CH2)6CH3、-(CH2)7CH3、-(CH2)10CH3、-(CH2)11CH3、-(CH2)12CH3、-(CH2)13CH3、-CH＝CHCH3、-(CH2)7CH＝CH(CH2)6CH3、-(CH2)7CH＝CH(CH2)7CH3、
3. The tetravalent platinum complex with a BET inhibitor of claim 2, wherein said tetravalent platinum complex with a BET inhibitor is one of the following structures:
4. use of a tetravalent platinum complex comprising a BET inhibitor according to any of claims 1 to 3 for the preparation of an antitumor medicament.
5. The use of a tetravalent platinum complex containing a BET inhibitor according to claim 4 for the preparation of an antitumor drug, wherein said tetravalent platinum complex containing a BET inhibitor is:
6. the use of the tetravalent platinum complex with BET inhibitor according to claim 4 for the preparation of an antitumor drug, wherein the tumor is selected from lung cancer, pancreatic cancer, liver cancer, breast cancer, cisplatin-resistant lung cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110637310.4A CN113336801B (en) | 2021-06-08 | 2021-06-08 | Tetravalent platinum complexes containing BET inhibitors and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110637310.4A CN113336801B (en) | 2021-06-08 | 2021-06-08 | Tetravalent platinum complexes containing BET inhibitors and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113336801A true CN113336801A (en) | 2021-09-03 |
| CN113336801B CN113336801B (en) | 2023-08-22 |
Family
ID=77475223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110637310.4A Active CN113336801B (en) | 2021-06-08 | 2021-06-08 | Tetravalent platinum complexes containing BET inhibitors and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113336801B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023093701A1 (en) * | 2021-11-26 | 2023-06-01 | 东南大学 | Platinum (ii) compound having targeting effect and derivative thereof, preparation method, pharmaceutical composition, and use |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105622674A (en) * | 2016-02-29 | 2016-06-01 | 东南大学 | Tetravalent platinum complex with bioactive group and preparation method of tetravalent platinum complex |
| CN109021026A (en) * | 2018-07-18 | 2018-12-18 | 浙江大学 | Cisplatin medicine precursor, preparation method and application |
| US20190169195A1 (en) * | 2016-04-12 | 2019-06-06 | The Regents Of The University Of Michigan | Bet protein degraders |
| CN111848690A (en) * | 2020-08-17 | 2020-10-30 | 南京大学 | Anticancer tetravalent platinum complex capable of inhibiting inflammation and immune escape and preparation method thereof |
-
2021
- 2021-06-08 CN CN202110637310.4A patent/CN113336801B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105622674A (en) * | 2016-02-29 | 2016-06-01 | 东南大学 | Tetravalent platinum complex with bioactive group and preparation method of tetravalent platinum complex |
| US20190169195A1 (en) * | 2016-04-12 | 2019-06-06 | The Regents Of The University Of Michigan | Bet protein degraders |
| CN109021026A (en) * | 2018-07-18 | 2018-12-18 | 浙江大学 | Cisplatin medicine precursor, preparation method and application |
| CN111848690A (en) * | 2020-08-17 | 2020-10-30 | 南京大学 | Anticancer tetravalent platinum complex capable of inhibiting inflammation and immune escape and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| XIAO ZHOU等: "BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells", 《ONCOLOGY REPORTS》, vol. 45, no. 70, pages 6 * |
| YINAN WANG等: "Synergistic Therapy for Cervical Cancer by Codelivery of Cisplatin and JQ1 Inhibiting Plk1-Mutant Trp53 Axis", 《NANO LETT.》, vol. 21, pages 2412 - 2421 * |
| 田迎棠等: "国产异长春花碱联合顺铂治疗晚期非小细胞肺癌", 《中原医刊》, vol. 33, no. 17, pages 73 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023093701A1 (en) * | 2021-11-26 | 2023-06-01 | 东南大学 | Platinum (ii) compound having targeting effect and derivative thereof, preparation method, pharmaceutical composition, and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113336801B (en) | 2023-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113072588B (en) | Tetravalent platinum complex containing artesunate and preparation method and application thereof | |
| CN108125944A (en) | A kind of taxol and CDKS kinase inhibitor antineoplastic combination pharmaceutical compositions | |
| CN107955042B (en) | Platinum complex with anticancer activity, preparation method and application | |
| CN111205331B (en) | Anti-tumor tetravalent platinum complex with anti-drug resistance function and preparation method thereof | |
| Albert et al. | Cyclopalladated and cycloplatinated benzophenone imines: Antitumor, antibacterial and antioxidant activities, DNA interaction and cathepsin B inhibition | |
| Chen et al. | Potential new inorganic antitumour agents from combining the anticancer traditional Chinese medicine (TCM) liriodenine with metal ions, and DNA binding studies | |
| CN113698435A (en) | Tetravalent platinum complex containing p53-MDM2 inhibitor and preparation method and application thereof | |
| CN107629089A (en) | Tacrine platinum (II) complex of high activity and its synthetic method and application | |
| CN111249283A (en) | Pyrimidine derivatives having anticancer effect | |
| CN113336801A (en) | Tetravalent platinum complex containing BET inhibitor and application | |
| CN103739616A (en) | Thiazolyl-containing rapamycin type derivative and application thereof | |
| Chellan et al. | Bioactive half-sandwich Rh and Ir bipyridyl complexes containing artemisinin | |
| Saroya et al. | Pentacoordinated diorganotin (IV) complexes of Schiff base ligands: synthesis, characterization, antimicrobial and anticancer studies | |
| CN113402565B (en) | Tetravalent platinum complex containing posaconazole, preparation method and application thereof | |
| CN114907417B (en) | Tetravalent platinum ternary complex containing artesunate and nonsteroidal anti-inflammatory drug as well as preparation method and application thereof | |
| CN102627685A (en) | Nitric oxide-donating glutathione compound, preparation method and medical purpose thereof | |
| WO2023155688A1 (en) | Oral pt (iv) anti-cancer prodrug axially containing 3-bromopyruvic acid ligand | |
| CN107445818B (en) | Cisplatin-flurbiprofen prodrug and preparation method and application thereof | |
| CN112940059B (en) | Glycosyl modified naphthalimide-polyamine conjugate, preparation method and application thereof | |
| CN113549122B (en) | Glycosylated tetravalent platinum compound targeting GLUTs, synthetic method and application thereof | |
| CN108484637A (en) | Target anticancer new drug X-76 salt-forming compounds and application thereof, preparation method | |
| CN110437149B (en) | Natural naphthyl isoquinoline compound with antitumor activity, and composition and application thereof | |
| CN103193742B (en) | Xanthatin derivative and medicine use thereof | |
| CN111393368A (en) | Indenopyrazole hydrochloride derivative and preparation method and application thereof | |
| CN115746060A (en) | Tetravalent platinum complex containing APR-246 and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |